RXElite

RXElite EV/EBIT

EV/EBIT (Enterprise Value to EBIT) of RXElite (RXEI) as of Oct 26, 2026.

EV/EBIT

-0.00

Last updated:

EV/EBIT (Enterprise Value to EBIT) of RXElite is 2007 -0.00 . EV/EBIT (Enterprise Value to EBIT) of RXElite was 2006 - . It decreases by % lower compared to the previous year.

The RXElite EV/EBIT history

The RXElite EV/EBIT history
YEAREV/EBITYoY
-0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RXElite Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides RXElite's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates RXElite's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots RXElite's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if RXElite grows earnings faster than its peers.

RXElite Stock analysis

What does RXElite do? RXElite Inc is a US-based company operating in the pharmaceutical and biotechnology sector. The company was founded in 1999 and is headquartered in Phoenix, Arizona. RXElite Inc specializes in the manufacturing and marketing of innovative medications and therapies developed and produced for both the American and international markets. RXElite Inc has various divisions and business sectors that focus on different demand patterns within the pharmaceutical and biotech industry. One area in which the company operates is the manufacturing of prescription medications, including prescription pain relievers and medications for inflammation and other diseases. Furthermore, RXElite Inc is involved in the development and manufacturing of generic drugs, which have the same active ingredient composition as existing brand-name medications. Generics are typically more affordable than brand-name medications and can result in cost savings for patients. Another business segment of RXElite Inc is the production of dietary supplements and vitamin preparations. The company uses natural ingredients and emphasizes high quality to meet the increasing demands of customers. RXElite Inc also operates in the field of medical device development and marketing, aiming to improve the diagnosis and treatment of diseases. This includes devices for measuring blood pressure or blood sugar levels, as well as ventilators. The RXElite Inc business model is diversified, aiming to meet existing market needs and explore new market segments. The company combines research, development, and production to provide customers with innovative and high-quality products. In recent years, RXElite Inc has expanded its portfolio and strengthened its position in the pharmaceutical and biotech sector through various acquisitions and partnerships. One important acquisition was the takeover of American Wholesale Distributors in 2006, which provided RXElite Inc with access to a broader customer base and new markets. International expansion is another focus of RXElite Inc. The company has opened several branches in Asia, Europe, and Latin America to increase its market share and expand its global presence. RXElite Inc places great emphasis on innovation and research and development. The company continuously invests in the exploration of new active ingredients and manufacturing processes for medications. RXElite Inc also has strong partnerships with various universities and research institutions to strengthen collaboration and promote the exchange of ideas and expertise. Overall, RXElite Inc is a dynamic and diversified company that occupies a leading position in the pharmaceutical and biotech sector due to its comprehensive portfolio of products and services, as well as its global reach. RXElite Inc strives to meet the needs of its customers and strengthen its position in the market through continuous innovation and expansion. RXElite is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RXElite stock

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) RXElite since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s RXElite with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — RXElite

All Key Metrics — RXElite